Renoprotective Effects of Dapagliflozin in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Diabetes Mellitus, Type 2Diabetic Nephropathies

Interventions

DRUG

Dapagliflozin 10mg QD

Dapagliflozin 10mg once daily for 12 weeks

DRUG

Gliclazide 30mg QD

Gliclazide30mg once daily for 12 weeks

Trial Locations (1)

VU University Medical Center, Amsterdam